MALAGA, Spain—Patients with obesity treated with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy; Novo Nordisk) can achieve weight loss in the real world similar to what has ...

A new once-a-month injection helped people with obesity shed up to 16% of their body weight, offering fresh hope for effective, long-acting treatments. Can this breakthrough change the landscape for ...

Credit: Getty Images By reinforcing the essential role of exercise, health care providers can ensure that GLP-1 therapy leads to weight loss, sustains muscle mass, and improves functional health.